Trial Profile
A multi-center, open-label, Phase I study of single agent RO5045337 administered orally in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) in blast phase, or refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SCLL).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 7112 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 12 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.